原发性旁路术与原发性血管成形/支架术治疗下肢慢性肢体威胁性缺血的比较结果
该回顾性研究纳入2005至2014年间单中心1336例首次因慢性肢体威胁性缺血(CLTI)行下肢血运重建的患者(旁路术668例,PTA/S 668例)。旁路术组6个月伤口愈合率更高(43% vs 36%),3年免于再干预率(62% vs 52%)和免于再狭窄率(61% vs 45%)更优,但住院总天数更长且手术部位感染发生率为10%。围术期死亡率和 major 截肢率两组相似。
要点
- 首次旁路术较PTA/S再干预更少、再狭窄率更低、伤口愈合更好。
- 旁路术住院时间更长且手术部位感染发生率为10%。
- 大截肢风险由坏疽、透析依赖、糖尿病和TASC D病变预测,而非术式。
核心结论
- 首次旁路术治疗CLTI在3年内再干预更少、再狭窄率更低、通畅率更高、伤口愈合更好且生存更优。
- 旁路术与住院总天数增加和伤口感染相关,但围术期死亡率和截肢率与PTA/S相似。
研究设计与样本
- 回顾性分析2005至2014年单中心血管外科所有首次因CLTI行下肢血运重建的患者。
- 共纳入1336例符合标准者,旁路术668例,PTA/S 668例。
- 采用χ2检验、Kaplan-Meier法和Cox回归分析结局。
主要发现
- 旁路术组患者更年轻(71 vs 72岁;P=.02),男性比例更高(62% vs 56%;P<.02)。
- 旁路术组总住院天数更长(10 vs 8天;P<.001),术前住院天数(4 vs 3天;P<.01)和术后住院天数(7 vs 5天;P<.001)均更长。
- 围术期死亡率两组无差异(3% vs 3%;P=.63),旁路术组手术部位感染发生率为10%。
- 3年免于再干预率旁路术组更高(62% vs 52%;P=.04),3年免于再狭窄率也更高(61% vs 45%;P<.001)。
- 6个月完全伤口愈合率旁路术组更优(43% vs 36%;P<.01)。
关键数值与推荐
- Cox回归显示再干预的预测因素包括首次PTA/S(HR 1.6;95%CI 1.3-2.1)、术前股腘动脉TASC C病变(HR 2.0;95%CI 1.3-3.1)和TASC D病变(HR 1.8;95%CI 1.3-2.7)。
- 大截肢的预测因素包括初诊坏疽(HR 2.5;95%CI 1.3-5.0)、透析依赖(HR 1.9;95%CI 1.3-2.9)、糖尿病(HR 2.0;95%CI 1.1-3.8)和术前股腘动脉TASC D病变(HR 2.1;95%CI 1.1-4.0),术式不是预测因素。
临床怎么用
- 对于适合旁路术的CLTI患者,首次旁路术可减少再干预、再狭窄并改善伤口愈合,但需权衡住院时间延长和伤口感染风险。
- 大截肢风险主要取决于坏疽、透析依赖、糖尿病和TASC D病变,而非血运重建方式。
局限性
- 回顾性单中心研究,存在选择偏倚可能。
- 仅纳入首次干预患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term results comparing percutaneous transluminal angioplasty with or without stenting (PTA/S) and open surgical bypass for chronic limb-threatening ischemia (CLTI) in patients who have had no prior intervention are lacking. METHODS: All patients undergoing a first-time lower extremity revascularization for CLTI by vascular surgeons at our institution from 2005 to 2014 were retrospectively reviewed. Outcomes included perioperative complications, wound healing, restenosis, primary patency, reintervention, major amputation, RAS events (ie, reintervention, major amputation, or stenosis), and mortality. Outcomes were evaluated using χ2, Kaplan-Meier, and Cox regression analyses. RESULTS: Of the 2869 total lower extremity revascularizations performed between 2005 and 2014, there were 1336 that fit our criteria of a first-time lower extremity intervention for CLTI (668 bypass procedures and 668 PTA/S procedures). Bypass patients were younger (71 vs 72 years; P = .02) and more often male (62% vs 56%; P < .02). Total mean hospital length of stay (LOS) was significantly longer after a first-time bypass (10 vs 8 days; P < .001), as were mean preoperative LOS (4 vs 3 days; P < .01) and postoperative LOS (7 vs 5 days; P < .001). There was no difference in perioperative mortality (3% vs 3%; P = .63). Surgical site infection occurred in 10% of bypass patients. Freedom from reintervention was significantly higher in patients undergoing a first-time bypass procedure (62% vs 52% at 3 years; P = .04), as was freedom from restenosis (61% vs 45% at 3 years; P < .001). Complete wound healing at 6-month follow-up was significantly better after an initial bypass (43% vs 36%; P < .01). A Cox regression model of all patients showed that reintervention was predicted by a first-time PTA/S (hazard ratio, 1.6; 95% confidence interval, 1.3-2.1) and both preoperative femoropopliteal TransAtlantic Inter-Society Consensus (TASC) C and TASC D lesions (2.0 [1.3-3.1] and 1.8 [1.3-2.7], respectively). Major amputation among all patients was predicted by an initial presentation of gangrene (2.5 [1.3-5.0]), dialysis dependence (1.9 [1.3-2.9]), diabetes (2.0 [1.1-3.8]), and preoperative femoropopliteal TASC D lesions (2.1 [1.1-4.0]) and was not predicted by procedure type. CONCLUSIONS: In this retrospective analysis, bypass for the primary treatment of CLTI showed improved 6-month wound healing, higher freedom from restenosis, improved patency rates, significantly fewer reinterventions, and higher survival than PTA/S within 3 years; however, a bypass-first approach was associated with increased total hospital LOS and wound infection. Perioperative mortality and amputation rates were similar between procedure types.
引用
- Darling JD, McCallum JC, Soden PA, et al. Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia. J Vasc Surg. 2017. PMID: 28274753. doi:10.1016/j.jvs.2017.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。